Salute e Benessere
Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at the 2025 American Association for Cancer Research (AACR) Annual Meeting
ADCE-D01 is a first-in-class ADC targeting uPARAP conjugated to the Topo-1 inhibitor payload P-1021. uPARAP is a novel endocytic ADC target that is overexpressed in tumors of mesenchymal origin, such as sarcomas, while exhibiting restricted expression in normal tissues. ADCE-D01 is composed of a first-in-class uPARAP-targeting antibody conjugated to an optimized, clinically validated linker payload technology, selected for its superior efficacy and tolerability. Preclinically, ADCE-D01 shows strong anti-tumor activity in a range of mesenchymal tumor models including soft tissue sarcoma and is well tolerated in non-human primate toxicology studies with a favorable safety profile and no evidence of target-specific toxicity. A phase 1 clinical trial in advanced soft tissue sarcomas is enrolling in the United States and is under regulatory review in the European Union [NCT06797999].
: "We are excited to share the promising preclinical data for ADCE-T02 and ADCE-D01 demonstrating strong anti-tumor activity across a broad range of epithelial and mesenchymal tumor models with highly favourable tolerability profiles. We look forward to advancing both programs in our phase 1 Tiffany-01 and ADCElerate1 trials to help cancer patients in need of novel therapeutic options."
ADCE-T02: A first-in-class topoisomerase-1 inhibitor-based antibody drug conjugate against tissue factor demonstrates excellent preclinical efficacy and tolerability
T. T. Poulsen , Y. Zhang , J. Zhang , H. Shi , S. Liu , X. Meng , M. Gillberg , D. Mumberg Adcendo ApS, Copenhagen, Denmark .
Multitude Therapeutics, Shanghai, China .
Multitude Therapeutics, Redwood City, CA , USA
ADCE-D01: a first in class antibody-drug conjugate against urokinase plasminogen activator receptor-associated protein (uPARAP) demonstrates excellent preclinical efficacy and tolerability
J. Wardman , A. Bie , C. Côme , P. Barkholt , S. van Putten , C. Løkke , I. Gregersen , J. Lange , M. Gilberg , K. Bannister , M. Krogh-Madsen , T. T. Poulsen , C. Nielsen , L. Engelholm , N. Behrendt , C. Lynch , P. Hemmingsen , D. Mumberg Adcendo ApS, Copenhagen, Denmark .
The Finsen Laboratory, Rigshospitalet/BRIC,
Copenhagen University , Copenhagen, Denmark
Abstracts are available in an online itinerary planner (ADCE-T02 abstract; ADCE-D01 abstract), and will be available in an online only supplement to the AACR journal Cancer Research one month after the conference. Electronic posters will be made available for registered conference participants from April 25 , 2025, through the conference web portal.
ADCs are a class of highly potent biopharmaceutical drug composed of a targeting antibody linked to a biologically active drug or cytotoxic compound. ADCs combine the unique and very sensitive targeting capabilities of antibodies, with the potent effects of the conjugated cytotoxic drugs, allowing sensitive discrimination between healthy and cancer tissues.
is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark , with operations in Boston, Massachusetts . The company is developing a pipeline of first- and potential best-in-class antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs. Led by a team of industry veterans with a track record of advancing multiple ADCs to approval, Adcendo integrates novel targets, optimized linker-payload combinations, and a rationally designed development strategy to drive next-generation cancer therapies. www.adcendo.com LinkedIn
Logo - https://mma.prnewswire.com/media/2565778/Adcendo_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/adcendo-aps-to-present-data-on-its-clinical-stage-adcs-adce-t02-and-adce-d01-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting-302435264.html